Trial · NCT06620393
Effects of Dexmedetomidine on Agitation in Critically Ill TBI Patients
NCT06620393, Phase 2, Phase 3, Not yet recruiting, Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Dexmedetomidine on Agitation in Critically Ill TBI Patients. Trials, record NCT06620393. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06620393
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Dexmedetomidine on Agitation in Critically Ill TBI Patients
- NCT number
- NCT06620393
- Status
- Not yet recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 72 participants, estimated
- Lead sponsor
- Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
- Conditions
- Traumatic Brain Injury, Agitation,Psychomotor
- Interventions
- Dexmedetomidine, Placebo
- First posted
- 2024-10-01
- Last updated
- 2024-10-01
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Protocol adherence | Through study completion, an average of 2 years | Proportion of hours the drug was administered |
| Secondary | Trial recruitment | Through study completion, an average of 2 years | Recruitment rate and randomization/activation process (consent rate, proportion of recruited patients who receive the study drug) |
| Secondary | Blinding maintenance | Through study completion, an average of 2 years | Proportion of intensivists and nurses predicting study group assignment at the end of the study intervention and proportion of patients receiving propofol |
| Secondary | Proportion of data collection completed | Through study completion, an average of 2 years | Data collection completeness for agitation-related events, posttraumatic amnesia and cognitive recovery |
| Other | ICU-days free of agitation or coma within 14 days following randomization | During ICU stay up to 14 days | Number of ICU-days without agitation or coma within 14 days following randomization |
| Other | Agitation-related event during the ICU stay | Through study completion, an average of 2 years | Accidental device removal, self-extubation following randomization in the ICU |
| Other | Proportion of patients and the number of days exposed to antipsychotics, benzodiazepines and physical restraints | Through study completion, an average of 2 years | Exposure to antipsychotics, benzodiazepines and physical restraints after randomization during ICU stay |
| Other | Time to mechanical ventilation liberation (extubation), time to ICU and hospital discharge | Through study completion, an average of 2 years | Time to mechanical ventilation liberation (extubation), time to ICU and hospital discharge |
| Other | Time to emergence from posttraumatic amnesia | Through study completion, an average of 2 years | Time from randomisation to emergence from posttraumatic amnesia |
| Other | Cognitive recovery | Through study completion, an average of 2 years | Brief cognitive assessment in traumatology (EXACT) score (0-100 points); higher scores reflect better function |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06620393
GET https://conductscience.org/api/trials/v1/NCT06620393/registered